Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01103180 · ClinicalTrials.gov registry record · Phase 2
Selective Serotonin Reuptake Inhibitors (SSRIs) in Borderline Personality Disorder
A Phase 2 study, sponsored by University of Chicago.
- Terminated
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
NCT01103180 is a Phase 2 study that was terminated before completion, run by University of Chicago. The registered enrollment target is 70 participants.
The verdict
NCT01103180, a Phase 2 study, was terminated before completion, sponsored by University of Chicago.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
Study Summary
The goal of this study is to examine the effectiveness the selective serotonin reuptake inhibitor (SSRI) escitalopram (also known by the trade name "Lexapro") in reducing desire to self-harm and actual self-harming among young adults with borderline personality disorder who are also currently depressed. Subjects will receive either escitalopram or placebo for eight weeks. During this time subjects will be make weekly visits to see the psychiatrist and record their thoughts and feelings several times each day using an electronic diary.
Interventions
- DRUG Escitalopram
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2010-09 |
| Est. Completion | 2014-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01103180
The ClinicalTrials.gov registry entry for NCT01103180 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Escitalopram is the first listed.
NCT01103180 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01103180 about?
NCT01103180 is a clinical study titled "Selective Serotonin Reuptake Inhibitors (SSRIs) in Borderline Personality Disorder". The goal of this study is to examine the effectiveness the selective serotonin reuptake inhibitor (SSRI) escitalopram (also known by the trade name "Lexapro") in reducing desire to self-harm and actual self-harming among young adults with borderline personality disorder who are also currently depres...
What is the current status of trial NCT01103180?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2010-09. Estimated completion is 2014-11.
What interventions are being tested in trial NCT01103180?
The interventions under investigation include: Escitalopram (DRUG).
Who is sponsoring clinical trial NCT01103180?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.